#USA #New York #Onassis Holdings #Dalmore Group #Mini IPO

Onassis Holdings Partners with Dalmore Group for Regulation A+ Offering

Onassis Holdings Corp (OTC: ONSS), a biotechnology-focused holding company, has recently announced an exciting financing strategy. The firm has engaged investment bank Dalmore Group to launch a Regulation A+ offering, which could raise as much as $75 million. This collaboration marks a significant step in Onassis's efforts to secure funding for its innovative endeavors in the biotech sector.

Founded with the mission to advance longevity and rejuvenation technologies through epigenetics, Onassis Holdings aims to transform its groundbreaking research into sustainable solutions for aging. The recent partnership with Dalmore Group is expected to streamline their fundraising process, utilizing Dalmore's extensive experience and connections within the financial industry. With a successful track record of over 2 billion dollars raised by various issuers, Dalmore Group brings an impressive portfolio of expertise in capital raising through different regulations.

The Power of Regulation A+

Regulation A+ is designed to simplify the process for companies to raise funds from the public, allowing them to gather up to $75 million annually. This legislation has increasingly attracted companies seeking innovative funding methods and tapping into a wider investor base. For Onassis, engaging with Dalmore Group not only presents a lucrative opportunity for capital but also positions them strategically within the biotech funding landscape, given the current market's inclination towards investment in health and longevity initiatives.

Under the agreement, Dalmore is set to leverage its established relationships across various financial markets, thus enhancing Onassis's visibility and outreach to potential investors. With over 16 years of experience, Dalmore offers strategic partnerships with marketing, PR experts, syndication partnerships with Reg A+ marketplace distribution platforms, and secondary trading solutions for issuers. This collaboration reflects a forward-thinking approach, marrying compliance with innovative fundraising tactics.

Onassis and Its Vision

At the core of Onassis Holdings is a subsidiary company, Ananda Labs Inc., which is spearheading research into revolutionary therapies based on patented proteins designed to rejuvenate elderly cells while preserving their unique characteristics. The ambition of Ananda Labs ties closely to Onassis’s overarching mission of enhancing life quality through biotechnology. By harnessing the power of epigenetics, the companies aim to create treatments that could redefine aging, portraying a future where it's possible to extend healthy years significantly.

The biotech market has seen significant interest and investment in recent years, driven by increasing consumer demand for longevity solutions. As the global population ages, the urgency for such technologies grows, making regulatory support like Regulation A+ more relevant than ever. By tapping into this funding mechanism, Onassis Holdings not only positions itself competitively in the market but also affirms its commitment to addressing one of society's most pressing challenges—aging.

Looking Ahead

As Onassis Holdings gears up for this pivotal moment, the company remains focused on executing its strategic vision. With the backing of Dalmore Group and the framework provided by Regulation A+, the possibilities for growth and innovation seem promising. While the road ahead may include inherent risks, Onassis's proactive measures in securing funding signal confidence in their transformative approach to biotechnology.

In conclusion, this partnership not only accentuates the potential within the biotechnology sector but exemplifies how strategic collaborations can pave the way for the next generation of health solutions. As Onassis Holdings moves forward with its Regulation A+ offering, it invites investors to join in its journey towards redefining health and longevity through scientific advancements.

For further information on Onassis Holdings Corp and their initiatives, interested parties can reach out via +1-516-620-6794 or visit their website at www.ananda-labs.bio.